Table 2 Study schedule. T1-T3: from the first treatment period to the third treatment period. W7: 1 week after the end of treatment. M3: 3 months after the end of treatment. M6: 6 months after the end of treatment
Study schedule | ||||||
|---|---|---|---|---|---|---|
Period | Screening | Baseline | Treatment | End | Follow-up | |
Time | W-1 | W0 | W1-W6 | W7 | M3 | M6 |
Basic | ||||||
 Eligibility | √ |  |  |  |  |  |
 Demography | √ |  |  |  |  |  |
 Physical examination | √ |  |  |  |  |  |
 Medical history | √ |  |  |  |  |  |
 Informed consent | √ |  |  |  |  |  |
Outcomes | ||||||
 WOMAC |  | √ |  | √ | √ | √ |
 VAS |  | √ |  | √ | √ | √ |
 X-ray examination |  | √ |  | √ |  |  |
 Musculoskeletal ultrasound imaging |  | √ |  | √ |  |  |
 Plantar pressure measurement |  | √ |  | √ |  |  |
 Maximum knee circumference |  | √ |  | √ |  |  |
 Joint mobility |  | √ |  | √ |  |  |
Trial evaluation | ||||||
 Informed consent | √ |  |  |  |  |  |
 Adverse event |  |  | √ | √ |  |  |
 Safety evaluation |  |  | √ | √ |  |  |